Loading clinical trials...

Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment. | Clinical Trials | Clareo Health

COMPLETEDNA

Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.

Holter of Movement in Patients with Multiple Sclerosis. Acti-SEP Study: Controlled Environment.

NCT04888689•Laurent Servais

Summary

ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. We plan to include a group of approximately 20 patients with MS. This study include a unique evaluation in the laboratory of analysis of human movement. A set of tasks will be performed by patients wearing of two magneto-inertial sensors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed MS diagnosis,
•Over 18 years old,
•Ambulant patients,
•Signed informed consent,
•No clinical and / or radiological relapse within 3 months.

Exclusion Criteria

•Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
•Any other previous or present pathology having an impact on motor function.
•Recent surgery or trauma (less than 6 months) in the upper or lower limbs

Locations (1)

Centre Hospitalier Régional de la Citadelle

Liège, Liège, Belgium

Key Dates

Start Date

February 4, 2021

Primary Completion Date

September 30, 2021

Completion Date

September 30, 2021

Last Updated

February 12, 2025

Enrollment

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Actimyo°

DEVICE

IMU

DEVICE

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis